SCHEMBL7097739

SCHEMBL7097739

Cn1c(=O)n(Cc2ccc(Br)cc2)c(=O)c2cc(C(=O)O)ncc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 1/20 0.46
SLC22A8 Q8TCC7 1/20 0.46
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 3/20 0.44
HIF1A Q16665 3/20 0.44
PKM P14618 2/20 0.44
LMNA P02545 1/20 0.44
STAT6 P42226 1/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
POLB P06746 1/20 0.40
MAPK1 P28482 1/20 0.40
PARG Q86W56 1/20 0.40
TSHR P16473 1/20 0.40
HPGD P15428 1/20 0.40
HDAC1 Q13547 2/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7103058 0.90 MMP13 (0.47) MMP13SLC22A8ALDH1A1MAPTHIF1A
SCHEMBL6255569 0.90 MMP13 (0.53) MMP13SLC22A8MEN1KMT2AALDH1A1
SCHEMBL7018710 0.89 MMP13 (0.46) MMP13SLC22A8ALDH1A1MAPTPKM
SCHEMBL7014083 0.88 MAPK1 (0.55) MMP13SLC22A8MEN1KMT2AALDH1A1
SCHEMBL7100732 0.87 PIK3CD (0.51) MMP13SLC22A8ALDH1A1MAPTPKM
SCHEMBL7018972 0.85 GRIN1 (0.44) MMP13SLC22A8PARG
SCHEMBL7102299 0.84 GRIN1 (0.44) MMP13SLC22A8MAPK1
SCHEMBL7101277 0.84 TSHR (0.47) MEN1KMT2AALDH1A1PKMLMNA
SCHEMBL7022157 0.84 MAPT (0.53) MMP13SLC22A8KMT2AALDH1A1MAPT
SCHEMBL7097608 0.82 MAPT (0.47) MMP13SLC22A8ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368324-A1 QUINAZOLINES AS MMP-13 INHIBITORS Warner-Lambert Company LLC (US) 2003-12-10 EP disclosed
US-20020193377-A1 Quinazolines as MMP-13 inhibitors ANDRIANJARA CHARLES (FR) 2002-12-19 US disclosed
WO-2002064572-A1 QUINAZOLINES AS MMP-13 INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193377-A1 Quinazolines as MMP-13 inhibitors MMP13, MMP9, MMP3 MMP13 1/4885SLC22A8 315/4885MEN1 4715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.